Prevalence of adverse reactions after dengue vaccine in a young population, in Paraná

Vacuna contra el dengue y reacciones adversas

Authors

DOI:

https://doi.org/10.5433/1679-0367.2023v44n1p71

Keywords:

Immunization, Vaccination, Adverse Events

Abstract

Objective: the present study’s purpose is to demonstrate the prevalence of dengue vaccine adverse events and its correlation with sociodemographic and clinical characteristics.
Material and Methodology: as a cohort study, a questionnaire and phone interviews were applied to the young adults, and data was collected from a database of local services, the Laboratory Environment Manager of Paraná, and the Dengue Vaccination Control Application. The relation between variables and the presence of vaccine reaction was made via the chi-squared and Fisher exact tests, afterwards, the binary logistic regression method was applied.
Results: from 1,815 participants, 6.5% have had some reaction, systemic or local, after receiving the vaccine dose. The most recurrent reactions identified were headaches (59.6%), followed by malaise (32.1%), fever (26.6%), myalgia (22%), local pain (14.6%), considering the last one the only reaction present in three vaccine doses. The first vaccine dose has had a greater chance of reaction comparing to the subsequent doses (p<0.0001). Being female [OR 1.701 (1.144-2.5416), p<0.009] increased the chance of vaccine reaction; however, to have an underlying disease [OR 0.001(0.000-0.002), p=0.000] was a protective factor.
Conclusion: the study demonstrated low adverse reactions in the population vaccinated with the dengue vaccine.

 

Downloads

Download data is not yet available.

Author Biographies

Danielle Ruiz Miyazawa Ferreira, Universidade Esatdual de Londrina - UEL

Master's Degree in Clinical and Laboratory Pathophysiology from the Universidade Estadual de Londrina (UEL), Londrina, Paraná

Lucas Gabriel Capelari, Universidade Esatdual de Londrina - UEL

Graduation in Nursing from Faculdade Pitágoras de Londrina, Londrina, Paraná,

Ivana Teixeira Motta, Universidade Esatdual de Londrina - UEL

Graduation in Nursing from the Universidade Estadual de Londrina, Londrina, Paraná, Brazil. Responsible Nurse at LabImage Laboratory, Londrina, Paraná

Jaqueline Dario Capobiango, Universidade Estadual de Londrina - UEL

PhD in Health Sciences from the Universidade Estadual de Londrina, Londrina, Paraná, Brazil. Department professor of Pediatrics and Pediatric Surgery at the Health Sciences Center at the Universidade Estadual de Londrina, Londrina, Paraná

References

Arragain L, Dupont-Rouzeyrol M, O'Connor O, Sigur N, Grangeon JP, Huguon E, et al. Vertical transmission of dengue virus in the peripartum period and viral kinetics in newborns and breast milk: new data. J Pediatric Infect Dis. Soc. 2017;6:324-31. doi: 10.1093/jpids/piw058 DOI: https://doi.org/10.1093/jpids/piw058

Busch MP, Sabino EC, Brambilla D, Lopes ME, Capuani L, Chowdhury D, et al. Duration of dengue viremia in blood donors and relationships between donor viremia, infection incidence and clinical case reports during a large epidemic. J Infect Dis. 2016;214:49-54. doi: 10.1093/infdis/jiw122 DOI: https://doi.org/10.1093/infdis/jiw122

Capeding MR, Tran NH, Hadinegoro SR, Hj Muhammad Ismail HIH , Chotpitayasunondh T, Chua MN, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014,384:1358-65. doi:10.1016/S0140-6736(14)61060-6 DOI: https://doi.org/10.1016/S0140-6736(14)61060-6

Centers for Disease Control and Prevention. Dengue: CDC [Internet]. 2021 [cited 2023 Jun 12]. Available from: https://www.cdc.gov/dengue/.

Dayan GH, Garbes P, Noriega F, Sadovsky ADI, Rodrigues PM, Giuberti C, et al. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil. Am J Trop Med Hyg. 2013;89:1058-65. doi: 10.4269/ajtmh.13-0304 DOI: https://doi.org/10.4269/ajtmh.13-0304

Dengue vaccine: WHO position paper, september 2018 - recommendations. Vaccine. 2019;37(35):4848-9. doi: 10.1016/j.vaccine.2018.09.063 DOI: https://doi.org/10.1016/j.vaccine.2018.09.063

Dubey AP, Agarkhedkar S, Chhatwal J, Narayan A, Ganguly S, Wartel TA, et al. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial. Hum. Vaccines Immunother. 2016;12:512-8. doi: 10.1080/21645515.2015.1076598 DOI: https://doi.org/10.1080/21645515.2015.1076598

Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine-induced humoral immunity. Semin Immunopathol. 2019;41:239-49. doi: 10.1007/s00281-018-0726-5 DOI: https://doi.org/10.1007/s00281-018-0726-5

Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol. 2017;33:577-99. doi: 10.1146/annurev-cellbio-100616-060718 DOI: https://doi.org/10.1146/annurev-cellbio-100616-060718

Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. Nat Rev Dis Primers. 2016;2:16055. doi: 10.1038/nrdp.2016.55 DOI: https://doi.org/10.1038/nrdp.2016.55

Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373:1195-1206. doi: 10.1056/NEJMoa1506223 DOI: https://doi.org/10.1056/NEJMoa1506223

Hirve S, Newman LP, Paget J, Azziz-Baumgartner E, Fitzner J, Bhat N, et al. Influenza seasonality in the tropics and subtropics - When to vaccinate? PLoS One. 2016;11(4):e0153003. doi: 10.1371/journal.pone.0153003 DOI: https://doi.org/10.1371/journal.pone.0153003

Khobragade AW, Kadam DD. Efficacy of tetravalent dengue vaccine: a systematic review and meta-analysis. Indian J Community Med. 2021,46:191-4. doi: 10.4103/ijcm.IJCM_608_20

Kimberlin, David W; Barnett, Elizabeth, Lynfield Ruth, editors. Red Book 2021: report of the Committee on Infectious Diseases [Internet]. Itasca: American Academy of Pediatrics; 2021 [cited 2023 Jun 10]. Available from: http://www.reddepadressolidarios.com/img/1rps_1634118322_a.pdf. DOI: https://doi.org/10.1542/9781610025225

Kraemer MUG, Reiner Jr RC, Brady OJ, Messina JP, Gilbert M, Pigott DM, Kraemer MUG, et al. Past and future spread of the arbovirus vectors Aedes aegypti and Aedes albopictus. Nat Microbiol. 2019;4: 854-63. doi:10.1038/s41564-019-0376-y DOI: https://doi.org/10.1038/s41564-019-0376-y

Leo YS, Wilder-Smith A, Archuleta S, Shek LP, Chong CY, Leong HN, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore. Hum. Vaccines Immunother. 2012;8:1259-71. doi: 10.4161/hv.21224 DOI: https://doi.org/10.4161/hv.21224

Nath KD, Burel JG, Shankar V, Pritchard AL, Towers M, Looke D, et al. Clinical factors associated with the humoral immune response to influenza vaccination in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014;9:51-6. doi: 10.2147/COPD.S53590 DOI: https://doi.org/10.2147/COPD.S53590

Organização Pan-Americana da Saúde. Dengue [Internet]. 2021 [citado 2023 jun 13]. Disponível em: https://www.paho.org/pt/topicos/dengue.

Ruggierii A, Anticoli S, D’ambrosio A, Giordani L, Mora M. The influence of sex and gender on immunity, infection and vaccination. Ann Ist Super Sanita. 2016;52:198-204. doi: 10.4415/ANN_16_02_11

Sabino EC, Loureiro P, Lopes ME, Capuani L, McClure C, Chowdhury D, et al. Transfusion-Transmitted dengue and associated clinical symptoms during the 2012 epidemic in Brazil. J Infect Dis. 2016;213:694-702. doi: 10.1093/infdis/jiv326 DOI: https://doi.org/10.1093/infdis/jiv326

Sanofi Pasteur. Dengvaxia: um guia de referência rápido para auxiliar profissionais de saúde [Internet]. 2019 [citado 2023 jun 10]. Disponível em: https://sbmt.org.br/wp-content/uploads/2019/03/PDF2.pdf.

Segerstrom SC, Hardy JK, Evans DR, Greenberg RN. Vulnerability, distress, and immune response to vaccination in older adults. Brain Behav Immun. 2012,26:747-53. doi: 10.1016/j.bbi.2011.10.009 DOI: https://doi.org/10.1016/j.bbi.2011.10.009

Sociedade Brasileira de Medicina Tropical. ANVISA atualiza bula da vacina contra a dengue [Internet]. 2019 [citado 2023 jun 12]. Disponível em: https://www.sbmt.org.br/portal/material-informativo-dengvaxia/

Sociedade de Pediatria do Estado do Rio de Janeiro. Perguntas e respostas vacinação contra dengue [Internet]. Rio de Janeiro: SOPERJ; 2019 [citado 2023 jun 8]. Disponível em: http://soperj.com.br/perguntas-respostas-vacinacao-contra-dengue/.

Tully D, Griffiths CL. Dengvaxia: the world's first vaccine for prevention of secondary dengue. Ther Adv Vaccines Immunother. 2021;9:25151355211015839. doi: 10.1177/25151355211015839 DOI: https://doi.org/10.1177/25151355211015839

Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol. 2007;5(7):518-28. doi: 10.1038/nrmicro1690 DOI: https://doi.org/10.1038/nrmicro1690

Wiggins KB, Smith MA, Schultz-Cherry S. The nature of immune responses to influenza vaccination in high-risk populations. Viruses. 2021;13(6):1109. doi: 10.3390/v13061109 DOI: https://doi.org/10.3390/v13061109

Wilder-Smith A. Dengue vaccine development by the year 2020: challenges and prospects. Curr Opin Virol. 2020;43:71-8. doi: 10.1016/j.coviro.2020.09.004 DOI: https://doi.org/10.1016/j.coviro.2020.09.004

World Health Organization. Background paper on dengue vaccines: prepared by the SAGE working group on dengue vaccines and WHO secretariat [Internet]. 2016 [cited 2023 Jun 10]. Available from: http://www.who.int/immunization/sage/meetings/2016/april/1_Background_Paper_Dengue_Vaccines_2016_03_17.pdf.

Zimmermann P, Curtis N. Factors That influence the immune response to vaccination. Clin Microbiol Rev. 2019;32(2):e00084-18. doi: 10.1128/CMR.00084-18 DOI: https://doi.org/10.1128/CMR.00084-18

Published

2023-07-31

How to Cite

1.
Ruiz Miyazawa Ferreira D, Capelari LG, Teixeira Motta I, Capobiango JD. Prevalence of adverse reactions after dengue vaccine in a young population, in Paraná: Vacuna contra el dengue y reacciones adversas. Semin. Cienc. Biol. Saude [Internet]. 2023 Jul. 31 [cited 2024 Nov. 21];44(1):71-80. Available from: https://ojs.uel.br/revistas/uel/index.php/seminabio/article/view/47767

Issue

Section

Artigos